サマリー

The global nanomedicine market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 10% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.

Nanomedicine refers to specialized multi-functional drugs with programmable properties used for the treatment of diseases and repairing tissues at a molecular level. It involves the use of nanoparticles, nanotubes and nanodevices, such as imaging agents, nanorobots, biochips and polymer therapeutics, for the diagnosis, treatment and prevention of a disorder and analyzing the underlying pathophysiology. The nanoparticles include metal and metal oxides, liposomes and inorganic particles, which are used for transporting the drugs and targeting difficult to reach areas in the body. As a result, nanomedicine finds extensive applications for drug delivery, diagnostic imaging, vaccines, regenerative medicines and implants.

Nanomedicine Market Trends:
The increasing prevalence of chronic medical ailments across the globe is one of the key factors creating a positive outlook for the market. Nanomedicine is highly beneficial in the treatment of oncological, neurological, urological, infectious, ophthalmological, orthopedic, immunological and cardiovascular diseases. Moreover, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for nanomedicines to produce vaccines and nanocarrier systems with enhanced efficacies. In line with this, shifting preference for personalized medicines is also contributing to the growth of the market. Additionally, various technological advancements in the nanoscale technologies for improved diagnostic procedures are acting as other growth-inducing factors. Pharmaceutical manufacturers are using nanorobotic systems and other novel solutions for the effective administration of nanomedicines. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biotechnology, are anticipated to drive the market toward growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global nanomedicine market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, nanomolecule type, product and application.

Breakup by Nanomolecule Type:

Nanoparticles
Metal and Metal Oxide Nanoparticles
Liposomes
Polymers and Polymer Drug Conjugates
Hydrogel Nanoparticles
Dendrimers
Inorganic Nanoparticles
Nanoshells
Nanotubes
Nanodevices

Breakup by Product:

Therapeutics
Regenerative Medicine
In-Vitro diagnostics
In-Vivo diagnostics
Vaccines

Breakup by Application:

Clinical Oncology
Infectious Diseases
Clinical Cardiology
Orthopedics
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arrowhead Pharmaceuticals Inc., General Electric Company, Luminex Corporation, Merck & Co. Inc., Nanobiotix, Novartis AG, Pfizer Inc., Sanofi SA and Starpharma Holdings Limited. Key Questions Answered in This Report:
How has the global nanomedicine market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global nanomedicine market?
What are the key regional markets?
What is the breakup of the market based on the nanomolecule type?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global nanomedicine market and who are the key players?
What is the degree of competition in the industry?

ページTOPに戻る

目次

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Nanomedicine Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Nanomolecule Type
6.1 Nanoparticles
6.1.1 Market Trends
6.1.2 Major Types
6.1.2.1 Metal and Metal Oxide Nanoparticles
6.1.2.2 Liposomes
6.1.2.3 Polymers and Polymer Drug Conjugates
6.1.2.4 Hydrogel Nanoparticles
6.1.2.5 Dendrimers
6.1.2.6 Inorganic Nanoparticles
6.1.3 Market Forecast
6.2 Nanoshells
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Nanotubes
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Nanodevices
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Product
7.1 Therapeutics
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Regenerative Medicine
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 In-Vitro Diagnostics
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 In-Vivo Diagnostics
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Vaccines
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Application
8.1 Clinical Oncology
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Infectious Diseases
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Clinical Cardiology
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Orthopedics
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Arrowhead Pharmaceuticals Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 General Electric Company
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.4 Luminex Corporation
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Merck & Co. Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Nanobiotix
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 Novartis AG
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Pfizer Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Sanofi SA
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Starpharma Holdings Limited
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials